scholarly journals Diabetes registry and service in Nigerian suburban-based tertiary healthcare facility

Author(s):  
Fortunatus D. Gbeinbo ◽  
Eunice O. Igumbor ◽  
Otovwe Agofure ◽  
Chinedu O. Obodo ◽  
Emmanuel Olu-Ero ◽  
...  

Background: Diabetes register is a clinical tool necessary for patient management including follow-up and referral procedures. In the Bringing Research in Diabetes to Global Environments and Systems that is in progress in Delta State, Nigeria; part of focus is establishment of diabetes register at a tertiary health facility. This phase of the project aimed to establish a diabetes register and to assess the baseline data.Methods: This was a clinical observational descriptive study at Eku Baptist Government Hospital. The diabetes register developed as in previous report was adopted as a scale-up study. After due clearance from the hospital, patients’ hospital record files were screened for cases of diabetes and 70 files were identified. Data were analyzed descriptively using Microsoft Excel Data Analysis ToolPak 2010.Results: There was a 2/1 female/male ratio, while 6% were below 40 years. 90% of patients had blood glucose levels results that indicated poor diabetes control. There is problem of incomplete data collection, for instance <25% BMI data was available. Capability and opportunity for standard service, e.g. diabetic foot examination, lipid profile, renal and retinal assessment was available at the tertiary health facility to allow management and referral from other hospitals.Conclusions: This report highlights poor adherence to diabetes care practices by stakeholders. It underscores the need for motivation to improve the quality of clinical data collection vis-à-vis documentation that enables assessment of diabetes epidemiology, especially in a facility that has the capacity.

Author(s):  
Anthonia C. Okwelum ◽  
Eunice O. Igumbor ◽  
Otovwe Agofure ◽  
Pleasant C. Ndubueze ◽  
Kenneth Aninze ◽  
...  

Background: As part of series of advocacy on development of diabetes register, one of the target health facilities is private general practices. In suburban Kwale community Delta State, Donak hospital was chosen to study the process of developing and implementing diabetes register program. Specific objectives include to evaluate the extent of completeness of data for patients follow-up, diabetes services within the private practice based on data collection, prevalence of high blood pressure, and patients’ compliance with medical appointments.Methods: The study followed a clinical observational method and after necessary ethical considerations, medical information was gotten from the record unit Donak Hospital, Kwale. The patients identified as potential diabetes or prediabetes were contacted for follow-up and 113 (65 females and 48 males) participants consented, all adults. Data collection were those required for a diabetes register proforma and were analyzed using Microsoft Excel Analysis Tool-pack. Results: There was no dedicated diabetes register per se except for usual medical records. The private practice has 100% record of contact details and blood pressure completeness for the participants. The scope of service offered to the patients was basically primary healthcare services. Over 50% of the participants have high blood pressure. On the patients’ compliance with medical check-up; only 23% of the participants complied with check-up appointments.Conclusions: The development of diabetes register in private practices can improve services. These services include documentation of appointments to enable follow-up strategies to encourage compliance to medical check-ups and a record diabetes education that may be provided.


2019 ◽  
Vol 14 (1) ◽  
pp. 65-74 ◽  
Author(s):  
Aravinth P. Jawahar ◽  
Siddharth Narayanan ◽  
Gopalakrishnan Loganathan ◽  
Jithu Pradeep ◽  
Gary C. Vitale ◽  
...  

Islet cell auto-transplantation is a novel strategy for maintaining blood glucose levels and improving the quality of life in patients with chronic pancreatitis (CP). Despite the many recent advances associated with this therapy, obtaining a good yield of islet infusate still remains a pressing challenge. Reprogramming technology, by making use of the pancreatic exocrine compartment, can open the possibility of generating novel insulin-producing cells. Several lineage-tracing studies present evidence that exocrine cells undergo dedifferentiation into a progenitor-like state from which they can be manipulated to form insulin-producing cells. This review will present an overview of recent reports that demonstrate the potential of utilizing pancreatic ductal cells (PDCs) for reprogramming into insulin- producing cells, focusing on the recent advances and the conflicting views. A large pool of ductal cells is released along with islets during the human islet isolation process, but these cells are separated from the pure islets during the purification process. By identifying and improving existing ductal cell culture methods and developing a better understanding of mechanisms by which these cells can be manipulated to form hormone-producing islet-like cells, PDCs could prove to be a strong clinical tool in providing an alternative beta cell source, thus helping CP patients maintain their long-term glucose levels.


2015 ◽  
Vol 56 (5) ◽  
pp. 344 ◽  
Author(s):  
JosephOlusesan Fadare ◽  
AdekunleOlaitan Adeoti ◽  
Felix Aina ◽  
OlusojiAbidemi Solomon ◽  
JoelOlatunde Ijalana

2019 ◽  
Vol 8 (2) ◽  
pp. 96
Author(s):  
ChidiebereD I Osuorah ◽  
Linda Nwokeji-Onwe ◽  
AbrahamB Onwe ◽  
KenechukwuK Iloh ◽  
Uzoamaka Muoneke ◽  
...  

Nursing Open ◽  
2020 ◽  
Vol 7 (3) ◽  
pp. 783-792
Author(s):  
Kennedy Diema Konlan ◽  
Juliana Asibi Abdulai ◽  
Kennedy Dodam Konlan ◽  
Roberta Mensima Amoah ◽  
Abdul‐Razak Doat

2017 ◽  
Vol 10 (1) ◽  
pp. 56-67 ◽  
Author(s):  
Justice Surage ◽  
Richard Tawiah ◽  
Timothy Twumasi-Mensah

Purpose The purpose of this paper is to measure the spatial accessibility of primary healthcare facility in Ghanaian rural areas, by determining the barriers to healthcare accessibilities in the Amansie Central District. Design/methodology/approach Both network and proximity analyses were performed on the digitized data such as road networks, settlements, population, district boundary, natural resources (rivers, streams and forest) and site location (health facilities). To quantify the population who have access to healthcare the authors used the Ghana Health Service access criteria that health facility should be accessible to an estimated population within 8 km radius from the facility. Findings The overall mean distance to the nearest health facility in the district was 8.9 km. Fiankoma sub-district recorded the highest mean distance whereas Tweapease sub-district recorded the least. In general, 31.2 percent of the district population has no access to healthcare facility. Transportation was identified to be one of the major hindrances to healthcare accessibility and this was as a result of poor road network in the district. Research limitations/implications The study was restricted to the Amansie Central District of Ghana. This limits the extent of generalization of results. Originality/value The study proposed additional sites for siting new health facilities base on criteria such as population, distance, centrality and existing infrastructural development. This will consequently improve healthcare accessibility and utilization by increasing total coverage closer to 100 percent.


2017 ◽  
Vol 64 (4) ◽  
pp. 304-311 ◽  
Author(s):  
Uchenna Ekwochi ◽  
Isaac Nwabueze Asinobi ◽  
Donatus Chidiebere Ignatius Osuorah ◽  
Ikenna Kingsley Ndu ◽  
Christain Ifediora ◽  
...  

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e18387-e18387
Author(s):  
Cynthia Villarreal-Garza ◽  
Cristel De la O-Maldonado ◽  
Héctor Díaz-Pérez ◽  
Fernanda Mesa-Chavez ◽  
Marisol García-García ◽  
...  

e18387 Background: The subcutaneous presentation of trastuzumab has been recently incorporated into the treatment regimen of HER2-positive breast cancer (BC). Its use has been associated with cost savings and reduced chair time, being especially suitable for public health systems. Aim: To estimate the cost savings of the use of SC-T compared to intravenous trastuzumab (IV-T) according to patient weight, and calculate the infusion time of SC-T in a tertiary healthcare facility at TecSalud from Feb 2018 - Jan 2019. Methods: From a total of 2068 oncological treatments, 756 corresponded to SC-T, either alone or concomitantly with chemotherapy (CT). For cost estimation, we considered $1,103 USD per SC-T vial, $1,162 USD per IV-T vial and $2.6 USD per mg of IV-T, as per governmental rates. We compared the actual treatment cost of 600 mg fixed SC-T dose with the hypothetical cost of administering IV-T at a dose of 6 mg/kg, considering its price per vial and per mg. The total time of SC-T infusion was reported. Results: Median patient weight for the 756 reported SC-T treatments was 72 kg (45 - 127 kg). Of these, 561 consisted of SC-T alone; and 56% had adjuvant, 34% neoadjuvant and 10% palliative intent. The estimated cost of the 756 doses of SC-T was $833,500 USD. Considering patients’ weight, 46% of the infusion treatments would have required 2 IV-T vials, with a total of 1105 vials and an absolute cost of $1,282,374 USD. Likewise, if cost per mg of IV-T is examined, we would have used 338,744 mg of IV-T, with an estimated cost of $894,284 USD. Approximate savings of SC-T use would reach $448,874 USD per vial payment and $60,784 USD per mg payment. The median time of SC-T only infusion was of 3 minutes (1 - 20 minutes); and no adverse effects were documented during its administration. Conclusions: The SC-T fixed dose (irrespectively of patients’ weight) results in significant practical and financial advantages as weight-adjusted dosing is not required. This is specially relevant in countries like Mexico, where > 70% of BC patients are overweight/obese, requiring higher doses of IV-T and resulting in greater expenses. Thus, the use of SC-T not only offers greater convenience to patients, but also reduces overall healthcare costs compared to standard IV infusion.


Sign in / Sign up

Export Citation Format

Share Document